Antiretroviral Agents — How Best to Protect Infants from HIV and Save Their Mothers from AIDS
Open Access
- 15 July 2004
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (3) , 289-292
- https://doi.org/10.1056/nejme048128
Abstract
Preventing transmission of human immunodeficiency virus type 1 (HIV-1) and caring for those already infected are essential services in any comprehensive program, and enhancing the mutually beneficial effect of each is an international goal.1 These reinforcing effects are clearly illustrated in the two articles from the Perinatal HIV Prevention Trial (PHPT) Group in this issue of the Journal. The first report, by Lallemant et al., demonstrates the considerable efficacy of a dual antiretroviral regimen in reducing mother-to-child transmission of HIV-1,2 whereas the second, by Jourdain et al., evaluates the effects of subsequent provision of highly active antiretroviral therapy (HAART) to the immunocompromised mothers.3Keywords
This publication has 9 references indexed in Scilit:
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in ThailandNew England Journal of Medicine, 2004
- HIV Type 1polGene Diversity and Archived Nevirapine Resistance Mutation in Pregnant Women in RwandaAIDS Research and Human Retroviruses, 2004
- Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6???8 Weeks After Single-Dose Nevirapine (HIVNET 012)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- The Interface of Perinatal HIV Prevention, Antiretroviral Drug Resistance, and Antiretroviral Treatment: What Do We Really Know?JAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316The Journal of Infectious Diseases, 2002
- Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV TransmissionA Randomized TrialJAMA, 2002
- Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)AIDS, 2001
- A Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000